Mechanism of Action of Resmetirom
Resmetirom is a liver-directed, selective thyroid hormone receptor-beta (THR-β) agonist that reduces intrahepatic triglycerides by stimulating hepatic lipophagy, mitochondrial biogenesis, and fatty acid oxidation while inhibiting hepatic lipogenesis and TGF-β-mediated fibrogenesis. 1
Primary Molecular Mechanism
Resmetirom functions as a partial agonist with high selectivity for THR-β over THR-α:
- THR-β activation: Produces 83.8% of maximum response compared to triiodothyronine (T3), with EC50 of 0.21 µM 1
- THR-α activity: Shows only 48.6% efficacy relative to T3, with EC50 of 3.74 µM (17-fold less potent) 1
- Tissue selectivity: THR-β is the predominant thyroid hormone receptor in the liver, while THR-α mediates most extrahepatic effects in heart and bone 1
This selectivity profile is critical—it allows therapeutic hepatic effects while minimizing systemic thyroid hormone-like adverse effects on cardiovascular and skeletal systems.
Hepatic Metabolic Effects
Through THR-β activation in hepatocytes, resmetirom triggers multiple coordinated metabolic pathways 2:
- Stimulates hepatic lipophagy: Enhances autophagy-mediated breakdown of lipid droplets
- Increases mitochondrial biogenesis: Improves hepatic oxidative capacity
- Promotes fatty acid oxidation: Accelerates hepatic lipid metabolism
- Inhibits de novo lipogenesis: Reduces new fat synthesis in the liver
- Enhances cholesterol turnover and lipoprotein remodeling: Improves lipid export from liver 3
Anti-Fibrotic Mechanisms
Beyond hepatocyte effects, resmetirom demonstrates direct anti-fibrotic activity 2:
- Inhibits TGF-β signaling: Interferes with the primary profibrogenic pathway
- Direct effects on hepatic stellate cells (HSCs): Recent evidence shows resmetirom acts on HSCs via THRα (which is more highly expressed in HSCs than hepatocytes) and increases fatty acid amide hydrolase (FAAH) expression, attenuating HSC activation 4
- Reduces midkine (MDK) expression: Decreases MDK-mediated M2 macrophage polarization and immunosuppression in the tumor microenvironment 5
Pharmacodynamic Effects
The molecular actions translate to measurable clinical effects 1:
- Reduces hepatic fat content: Demonstrated by MRI-PDFF and FibroScan CAP measurements
- Decreases prohormone FT4: By approximately 16-19% through upregulation of hepatic type 1 deiodinase (DIO1), which converts T4 to T3 exclusively in liver without central hypothalamic-pituitary-thyroid axis suppression 6
- Increases sex hormone-binding globulin (SHBG): Serves as a biomarker of target engagement, though free testosterone remains unchanged 6
Important Caveats
Off-target receptor binding: While resmetirom binds other nuclear receptors including constitutive androstane receptor (CAR), retinoic acid receptor-related orphan receptors (RORs), and hepatocyte nuclear factor 4α (HNF4α), functional studies demonstrate THR-β modulation remains dominant under physiological conditions 7. This off-target binding does not appear to compromise therapeutic efficacy.
Liver-directed delivery: Resmetirom is a substrate for hepatic uptake transporters OATP1B1 and OATP1B3, enhancing liver-specific accumulation and reducing systemic exposure 1. Overexpression of SLCO1B1 (encoding OATP1B1) increases resmetirom efficiency in both hepatocytes and HSCs 4.